Kurnaz-Gomleksiz , OzlemCanbay Torun, BaharIsbir,TurgayBulut,TurkerSokucu, NecmettinYilmaz-Aydogan, HulyaCanbay, Emel2022-06-282022-06-282022Kurnaz-Gomleksiz O, Torun BC, Isbir T, Bulut T, Sokucu N, Yilmaz-Aydogan H, Canbay E. The Role of PPAR-gamma C161T Polymorphism in Colorectal Cancer Susceptibility. In Vivo. 2022 Jul-Aug;36(4):1911-1915. doi: 10.21873/invivo.12911. PMID: 35738614.0258-851Xhttp://doi.org/10.21873/invivo.12911https://hdl.handle.net/20.500.12713/2949Background/aim: This study aimed to determine the role of the peroxisome proliferator-activated receptor-gamma (PPARg) C161T genotype and allele frequencies in predisposition to colorectal cancer (CRC). Patients and methods: PPARg C161T (His447His; rs3856806) gene polymorphisms were determined by polymerase chain reaction-restriction fragment length polymorphism analysis in patients with CRC (n=101) and controls (n=238). Results: The T161 allele (CT+TT genotypes) of PPARg C161T polymorphism was associated with CRC development (p<0.001; OR=3.239, 95%CI=1.997-5.252). Subgroup analysis showed that the T161 allele was associated with a 3.056-fold increased risk for colon cancer (CC) (p<0.001; 95%CI=1.709-5.464) and 3.529-fold increased risk for rectal cancer (RC) (p<0.001; 95%C=1.784-6.981). Frequencies of the T161 allele were also higher in total CRC and CC patients with poorly differentiated tumors (p<0.001, c2=30,601, OR=3.109; 95%CI=1.970-4.906 and p<0.001, Fisher exact test, respectively). Conclusion: PPARg T161 allele carriers have increased risk for developing CRC.eninfo:eu-repo/semantics/closedAccessPPARg C161T PolymorphismTurkish PopulationColorectal cancer (CRC)Article36141911191535738614WOS:0008189299000292-s2.0-85132680880Q410.21873/invivo.12911Q2